Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease and represents a major public health challenge worldwide.^1,2 It is a chronic, progressive neurological condition characterized primarily by motor symptoms, including resting tremor, bradykinesia, muscular rigidity, and postural instability.^3,4 In addition to these motor manifestations, patients frequently experience non-motor symptoms such as cognitive impairment, depression, sleep disturbances, autonomic dysfunction, and sensory abnormalities, which significantly affect quality of life. The prevalence of Parkinson’s disease increases with advancing age, making it one of the most important age-related neurological disorders.^5,6

The pathological hallmark of Parkinson’s disease is the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, a region of the midbrain responsible for the production of dopamine.^7,8 Dopamine is a critical neurotransmitter involved in the regulation of voluntary movement, motivation, reward, and cognitive function.⁹ The depletion of dopamine in the nigrostriatal pathway results in impaired communication between neuronal circuits that control movement, leading to the characteristic clinical symptoms of the disease.¹⁰ Another defining pathological feature is the presence of Lewy bodies, intracellular protein aggregates composed predominantly of α-synuclein, which accumulate within neurons and contribute to cellular dysfunction and death.

From a biochemical perspective, Parkinson’s disease is a multifactorial disorder involving complex interactions among genetic, environmental, and molecular factors.¹¹ Oxidative stress has emerged as a central mechanism in disease pathogenesis.¹² Dopaminergic neurons are particularly vulnerable to oxidative damage because dopamine metabolism generates reactive oxygen species (ROS) and other toxic metabolites. Excessive ROS production overwhelms endogenous antioxidant defense systems, resulting in lipid peroxidation, protein oxidation, DNA damage, and ultimately neuronal degeneration.¹³ Increased levels of oxidative stress biomarkers and reduced antioxidant enzyme activities have been consistently reported in patients with Parkinson’s disease.¹⁴

Mitochondrial dysfunction also plays a pivotal role in the biochemical basis of Parkinson’s disease. Mitochondria are responsible for cellular energy production through oxidative phosphorylation, and impairment of mitochondrial respiratory chain complexes, particularly Complex I, has been observed in affected brain tissues. ¹⁵ Defective mitochondrial function leads to reduced ATP production, increased generation of free radicals, and activation of apoptotic pathways that promote neuronal death.¹⁶ Furthermore, mutations in genes associated with mitochondrial quality control, including PINK1 and Parkin, have strengthened the link between mitochondrial abnormalities and Parkinson’s disease.

Another important biochemical mechanism is the abnormal aggregation and misfolding of α-synuclein. Under physiological conditions, α-synuclein participates in synaptic vesicle trafficking and neurotransmitter release. However, pathological alterations in protein folding promote the formation of toxic oligomers and fibrils that disrupt cellular homeostasis.¹⁷ These aggregates interfere with mitochondrial function, impair protein degradation systems such as the ubiquitin-proteasome pathway and autophagy-lysosomal pathway, and trigger inflammatory responses within the central nervous system.

Neuro inflammation has increasingly been recognized as a significant contributor to disease progression.¹⁸ Activated microglia release pro-inflammatory cytokines, reactive nitrogen species, and reactive oxygen species that exacerbate neuronal injury. Chronic inflammation creates a self-perpetuating cycle of oxidative stress and neurodegeneration, further accelerating the loss of dopaminergic neurons.¹⁹ In addition, genetic factors, including mutations in SNCA, LRRK2, PARK2, DJ-1, and PINK1, influence several biochemical pathways involved in protein homeostasis, mitochondrial integrity, and cellular stress responses.²⁰

Recent advances in biochemistry, molecular biology, proteomics, and metabolomics have greatly enhanced our understanding of the pathogenic mechanisms underlying Parkinson’s disease. These discoveries have facilitated the identification of novel biomarkers and therapeutic targets aimed at slowing neurodegeneration rather than merely alleviating symptoms. Consequently, investigating the biochemical alterations associated with Parkinson’s disease is essential for improving early diagnosis, monitoring disease progression, and developing effective disease-modifying therapies.

Therefore, this article focuses on the biochemical mechanisms involved in Parkinson’s disease, with particular emphasis on oxidative stress, mitochondrial dysfunction, α-synuclein aggregation, neuroinflammation, and molecular pathways contributing to neuronal degeneration. Understanding these biochemical processes may provide valuable insights into the development of innovative therapeutic strategies for this debilitating neurodegenerative disorder.

Study Design: This study was conducted as a comprehensive biochemical and molecular analysis of Parkinson’s disease Biochemical Analysis: Selected studies were analyzed to evaluate alterations in oxidative stress biomarkers (malondialdehyde, superoxide dismutase, catalase, and glutathione), mitochondrial function indicators, inflammatory mediators (TNF-α, IL-1β, and IL-6), and protein aggregation markers related to α-synuclein pathology. Evidence regarding genetic mutations influencing biochemical pathways was also assessed. Data Synthesis: The collected information was categorized according to major pathogenic mechanisms and integrated to establish a comprehensive biochemical framework describing the molecular events leading to dopaminergic neuronal degeneration in Parkinson’s disease. Outcome Measures The primary outcomes included identification of key biochemical alterations contributing to disease progression and potential molecular targets for therapeutic intervention. The findings were synthesized descriptively and presented through thematic analysis of the available evidence. This concise methodology provides a novel systems-biochemistry perspective by integrating oxidative, inflammatory, mitochondrial, proteostatic, and genetic mechanisms into a unified model of Parkinson’s disease pathogenesis.

A comprehensive analysis of the selected studies revealed that Parkinson’s disease is characterized by multiple interconnected biochemical disturbances that collectively contribute to dopaminergic neuronal degeneration.

Table 1. Oxidative Stress Biomarkers in Parkinson’s Disease

Finding: Elevated oxidative stress markers and diminished antioxidant defenses were consistently associated with neuronal injury and disease progression.

Table 2. Mitochondrial and Neuroinflammatory Alterations

Finding: Mitochondrial dysfunction and persistent neuroinflammation were major contributors to dopaminergic neuron loss and disease progression.

Table 3. Protein Aggregation and Neurotransmitter Changes

Finding: Abnormal α-synuclein accumulation disrupted protein homeostasis and was associated with dopamine depletion, resulting in the characteristic motor manifestations of Parkinson’s disease.

The present study highlights the complex biochemical mechanisms underlying Parkinson’s disease (PD), emphasizing the interconnected roles of oxidative stress, mitochondrial dysfunction, neuro inflammation, and α-synuclein aggregation in dopaminergic neuronal degeneration. The findings demonstrate that PD is not merely a disorder of dopamine deficiency but rather a multifactorial neurodegenerative condition involving widespread molecular and cellular disturbances.

One of the most significant observations was the elevation of oxidative stress markers accompanied by a reduction in endogenous antioxidant defenses. Increased levels of reactive oxygen species (ROS) and malondialdehyde (MDA), together with decreased activities of superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH), indicate a persistent state of oxidative imbalance. Dopaminergic neurons are particularly susceptible to oxidative injury because dopamine metabolism itself generates free radicals. Excessive oxidative stress damages lipids, proteins, and nucleic acids, ultimately leading to neuronal dysfunction and apoptosis. These findings are consistent with previous studies identifying oxidative stress as a central contributor to Parkinsonian neurodegeneration.

Mitochondrial dysfunction emerged as another critical pathogenic factor. Reduced activity of mitochondrial Complex I and diminished ATP production suggest impaired cellular energy metabolism in affected neurons. Mitochondria play a vital role in maintaining neuronal survival, and their dysfunction results in excessive ROS generation, calcium dysregulation, and activation of apoptotic pathways. The observed mitochondrial abnormalities support the hypothesis that defective bioenergetics contributes substantially to disease progression. Furthermore, genetic studies linking mutations in mitochondrial regulatory genes such as PINK1 and Parkin reinforce the importance of mitochondrial quality control in preventing neuronal loss.

The study also demonstrated increased neuroinflammatory activity characterized by elevated levels of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6. Chronic activation of microglia creates a toxic microenvironment that amplifies oxidative damage and accelerates neuronal degeneration. Rather than serving solely as a secondary response to neuronal injury, neuroinflammation appears to actively participate in disease progression through sustained release of inflammatory mediators. This observation suggests that anti-inflammatory therapeutic strategies may have potential value in slowing the progression of Parkinson’s disease.

1. Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z. Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries/territories from 1990 to 2019. Frontiers in public health. 2021 Dec 7;9:776847. 2. Su D, Cui Y, He C, Yin P, Bai R, Zhu J, Lam JS, Zhang J, Yan R, Zheng X, Wu J. Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. bmj. 2025 Mar 5;388. 3. Balestrino R, Schapira AH. Parkinson disease. European journal of neurology. 2020 Jan;27(1):27-42. 4. Radhakrishnan DM, Goyal V. Parkinson's disease: A review. Neurology India. 2018 Mar 1;66(Suppl 1):S26-35. 5. Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C. The epidemiology of Parkinson's disease. The Lancet. 2024 Jan 20;403(10423):283-92. 6. Bloem BR, Okun MS, Klein C. Parkinson's disease. The Lancet. 2021 Jun 12;397(10291):2284-303. 7. Ramesh S, Arachchige AS. Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature. AIMS neuroscience. 2023 Aug 14;10(3):200. 8. Speranza L, Di Porzio U, Viggiano D, de Donato A, Volpicelli F. Dopamine: the neuromodulator of long-term synaptic plasticity, reward and movement control. Cells. 2021 Mar 26;10(4):735. 9. Kaur S, Singh S, Jaiswal G, Kumar S, Hourani W, Gorain B, Kumar P. Pharmacology of dopamine and its receptors. InFrontiers in pharmacology of neurotransmitters 2020 Oct 30 (pp. 143-182). Singapore: Springer Singapore. 10. Pang SY, Ho PW, Liu HF, Leung CT, Li L, Chang EE, Ramsden DB, Ho SL. The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease. Translational Neurodegeneration. 2019 Aug 16;8(1):23. 11. Fleming SM. Mechanisms of gene-environment interactions in Parkinson’s disease. Current environmental health reports. 2017 Jun;4(2):192-9. 12. Reddy VP. Oxidative stress in health and disease. Biomedicines. 2023 Oct 29;11(11):2925. 13. Houldsworth A. Role of oxidative stress in neurodegenerative disorders: a review of reactive oxygen species and prevention by antioxidants. Brain Communications. 2024;6(1):fcad356. 14. Wei Z, Li X, Li X, Liu Q, Cheng Y. Oxidative stress in Parkinson's disease: a systematic review and meta-analysis. Frontiers in molecular neuroscience. 2018 Jul 5;11:236. 15. Park JS, Davis RL, Sue CM. Mitochondrial dysfunction in Parkinson’s disease: new mechanistic insights and therapeutic perspectives. Current neurology and neuroscience reports. 2018 May;18(5):21. 16. Dawson TM, Dawson VL. Mitochondrial mechanisms of neuronal cell death: potential therapeutics. Annual review of pharmacology and toxicology. 2017 Jan 6;57(1):437-54. 17. Louros N, Schymkowitz J, Rousseau F. Mechanisms and pathology of protein misfolding and aggregation. Nature Reviews Molecular Cell Biology. 2023 Dec;24(12):912-33. 18. Dias-Carvalho A, Sa SI, Carvalho F, Fernandes E, Costa VM. Inflammation as common link to progressive neurological diseases. Archives of toxicology. 2024 Jan;98(1):95-119. 19. Liu S, Liu J, Wang Y, Deng F, Deng Z. Oxidative stress: signaling pathways, biological functions, and disease. MedComm. 2025 Jul;6(7):e70268. 20. Dong-Chen X, Yong C, Yang X, Chen-Yu S, Li-Hua P. Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions. Signal transduction and targeted therapy. 2023 Feb 21;8(1):73.